Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Javier Puente

Head of the GU Cancer Unit

Hospital Clínico San Carlos

Research Interests

Explore related searches

Articles (20)

Collaborators (6)

Carole Harris

University of New South Wales

Yves Fradet

Full professor

Laval University

Ana Isabel Sanchez Fructuoso

Profesor Titular

Universidad Complutense de Madrid

Jesús Moreno Sierra

Profesor Titular

Universidad Complutense de Madrid

Jose Palma

Associate Professor in Computer Science and Artificial Intelligence

Universidad de Murcia

Armando Reyes-Palomares

University of Malaga

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Javier Puente

Research Interests

Explore related searches

Articles (20)

Collaborators (6)

Carole Harris

Yves Fradet

Ana Isabel Sanchez Fructuoso

Jesús Moreno Sierra

Jose Palma

Armando Reyes-Palomares

Make your next move.

Javier Puente

Research Interests

Explore related searches

Articles (20)

Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial.

Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) in Initial Staging of Prostate Cancer Patients: The Beginning of a New Era

Abiraterone-Associated Renal Damage in Patients with Advanced Prostate Cancer as a Risk Factor for Mortality and Chronic Kidney Disease

Real-world evidence in localized and locally advanced prostate cancer: applying artificial intelligence to electronic health records.

SEOM-SOGUG clinical guideline for urothelial cancer (2025).

Association of PD-1, LAG-3 and TIM-3 expression on intratumoral CD8 T-cells with response to atezolizumab in a Real-World-Evidence biomarker study for advanced urothelial carcinoma patients.

Real-world data on avelumab in first-line maintenance therapy for advanced or metastatic urothelial carcinoma: the SOGUG-AVELUMAB RWD study.

The spatial landscape of cancer hallmarks reveals patterns of tumor ecological dynamics and drug sensitivity.

Prognostic Implications of Blood Immune-Cell Composition in Metastatic Castration-Resistant Prostate Cancer

CRISPR/Cas9 screenings unearth protein arginine methyltransferase 7 as a novel essential gene in prostate cancer metastasis.

Correlation of safety and efficacy of atezolizumab therapy across indications.

Impact of COVID-19 infection on genitourinary cancer management. SOGUG-COVID-19: A spanish, multicenter, observational study.

Real-world treatment patterns, survival outcomes, and health care resource utilization for locally advanced or metastatic urothelial carcinoma in Spain.

Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non-small cell lung cancer.

Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study

Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study

Criteria and indicators to evaluate quality of care in genitourinary tumour boards

Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial

Management of Adverse Reactions Related to Lenvatinib Plus Pembrolizumab Treatment Among Patients With Renal Cell Carcinoma

Molecularly Defined Renal Carcinomas

Collaborators (6)

Carole Harris

Yves Fradet

Ana Isabel Sanchez Fructuoso

Jesús Moreno Sierra

Jose Palma

Armando Reyes-Palomares

Make your next move.